3-tert-butoxycarbonyl-1,3-thiazolidine-4-carboxamide | 1311448-68-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-tert-butoxycarbonyl-1,3-thiazolidine-4-carboxamide
• 英文别名: t-butyl 4-carbamoylthiazolidine-3-carboxylate；tert-butyl 4-carbamoyl-1,3-thiazolidine-3-carboxylate
• CAS: 1311448-68-6
• 化学式: C₉H₁₆N₂O₃S
• mdl: MFCD11616114
• 分子量: 232.304
• InChiKey: OXGKKJVYQKKOIS-UHFFFAOYSA-N

物化性质

• 沸点：
  419.6±45.0 °C(Predicted)
• 密度：
  1.256±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  97.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-tert-butoxycarbonyl-1,3-thiazolidine-4-carboxamide 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以80%的产率得到1,3-噻唑烷-4-甲酰胺
  参考文献：
  名称：

  Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome

  摘要：

  公开号：

  EP1595866B1
• 作为产物：
  描述：

  3-(叔丁氧羰基)噻唑烷-4-羧酸 在 N,N'-羰基二咪唑 、 氨 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 26.0h， 以81%的产率得到3-tert-butoxycarbonyl-1,3-thiazolidine-4-carboxamide
  参考文献：
  名称：

  Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome

  摘要：

  公开号：

  EP1595866B1

文献信息

• Compound inhibiting dipeptidyl peptidase IV
  申请人：Kakigami Takuji

  公开号：US20060229286A1

  公开（公告）日：2006-10-12

  A dipeptidyl peptidase IV inhibitor which is satisfactory in respect of activity, stability and safety and has an excellent action as a pharmaceutical agent. A compound represented by the following general formula or a pharmaceutically acceptable salt thereof: wherein R 1 and R 2 each represents hydrogen, an optionally substituted C1-6 alkyl group, or —COOR 5 whereupon R 5 represents hydrogen or an optionally substituted C1-6 alkyl group, or R 1 , R 2 , and a carbon atom together represent a 3- to 6-membered cycloalkyl group, R 3 represents hydrogen or an optionally substituted C6-10 aryl group, R 4 represents a hydrogen or a cyano group, D represents —CONR 6 —, —CO— or —NR 6 CO—, R 6 represents hydrogen or an optionally substituted C1-6 alkyl group, E represents —(CH 2 ) m — whereupon m is 1 to 3, —CH 2 OCH 2 —, or —SCH 2 —, n is 0 to 3, and A represents an optionally substituted bicyclic heterocyclic group or bicyclic hydrocarbon group.

  一种二肽基肽酶IV抑制剂，具有活性、稳定性和安全性方面的满意度，并且作为药物剂量具有优异的作用。该化合物由以下通式表示或其药学上可接受的盐：其中R1和R2分别表示氢、可选取代的C1-6烷基或-COOR5，其中R5表示氢或可选取代的C1-6烷基，或者R1、R2和一个碳原子共同表示3-6个成员的环烷基，R3表示氢或可选取代的C6-10芳基，R4表示氢或氰基，D表示-CONR6-、-CO-或-NR6CO-，R6表示氢或可选取代的C1-6烷基，E表示-(CH2)m-，其中m为1至3，-CH2OCH2-或-SCH2-，n为0至3，A表示可选取代的双环杂环基或双环烃基。
• (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING
  申请人：Ghosh Arun K.

  公开号：US20100286170A1

  公开（公告）日：2010-11-11

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.

  本发明提供了新型β-秘鲁酶抑制剂及其使用方法，包括治疗阿尔茨海默病的方法。
• [EN] N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES<br/>[FR] N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOÉTHYL)-QUINOLÉINE-4-CARBOXAMIDES
  申请人：ASTRAZENECA AB

  公开号：WO2022130270A1

  公开（公告）日：2022-06-23

  Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5and R6are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

  具有公式（I）结构及其药学上可接受的盐的化合物，其中X1，R1，R2，R3，R4，R5和R6如规范中所定义; 包括此类化合物和盐的制药组合物; 使用此类化合物和盐来治疗或预防脯氨酰内切酶成纤维细胞激活蛋白（FAP）介导的疾病; 包含此类化合物和盐的试剂盒; 以及制造此类化合物和盐的方法。
• COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV
  申请人：SANWA KAGAKU KENKYUSHO CO., LTD.

  公开号：EP1595866A1

  公开（公告）日：2005-11-16

  The invention aims to provide a dipeptidyl peptidase IV inhibitor which is satisfactory in respect of activity, stability and safety and has an excellent action as a pharmaceutical agent. The invention is directed to a compound represented by the following general formula or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each represents hydrogen, an optionally substituted C1-6 alkyl group, or -COOR5 whereupon R5 represents hydrogen or an optionally substituted C1-6 alkyl group, or R1 and R2, together with a carbon atom to which they are bound, represent a 3- to 6-membered cycloalkyl group, R3 represents hydrogen or an optionally substituted C6-10 aryl group, R4 represents a hydrogen or a cyano group, D represents -CONR6-, -CO- or -NR6CO-, R6 represents hydrogen or an optionally substituted C1-6 alkyl group, E represents -(CH2)m- whereupon m is an integer of 1 to 3, -CH2OCH2-, or -SCH2-, n is an integer of 0 to 3, and A represents an optionally substituted bicyclic heterocyclic group or bicyclic hydrocarbon group.

  本发明旨在提供一种二肽基肽酶 IV 抑制剂，该抑制剂在活性、稳定性和安全性方面都令人满意，并且作为药剂具有出色的作用。本发明涉及由以下通式代表的化合物或其药学上可接受的盐： 其中 R1 和 R2 各自代表氢、任选取代的 C1-6 烷基或 -COOR5 其中 R5 代表氢或任选取代的 C1-6 烷基，或 R1 和 R2 与它们结合的碳原子一起代表 3 至 6 元环烷基，R3 代表氢或任选取代的 C6-10 芳基、R4代表氢或氰基，D代表-CONR6-、-CO-或-NR6CO-，R6代表氢或任选取代的C1-6烷基，E代表-(CH2)m-，其中m为1至3的整数，-CH2OCH2-或-SCH2-，n为0至3的整数，A代表任选取代的双环杂环基团或双环烃基团。
• Effect of alkyl group on transnitrosation of N-nitrosothiazolidine thiocarboxamides
  作者：Keiko Inami、Yuta Ono、Sonoe Kondo、Ikuo Nakanishi、Kei Ohkubo、Shunichi Fukuzumi、Masataka Mochizuki

  DOI：10.1016/j.bmc.2015.09.008

  日期：2015.10

  S-Nitrosoglutathione (GSNO) relaxes vascular smooth muscles, prevents platelet aggregation, and acts as a potential in vivo nitric oxide donor. 3-Nitroso-1,3-thiazolidine-4-thiocarboxamide (1), a N-nitrosothioproline analogue, exhibited a high GSNO formation activity. In this study, two compounds (2 and 3) based on compound 1 were newly synthesized by introducing either one or two methyl groups onto a nitrogen atom on the thioamide substituent in 1. The pseudo-first-order rate constants (k(obs)) for the GSNO formation for the reaction between the compound and glutathione followed the order 1 > 2=3. Thus, the introduction of a methyl group(s) onto the thioamide group led to a decrease in the transnitrosation activity. On the basis of density functional theoretical calculations, the transnitrosation for the N-nitrosothiazolidine thiocarboxamides was proposed to proceed via a bridged intermediate pathway. Specifically, the protonated compound 1 forms a bridged structure between the nitrogen atom in the nitroso group and two sulfur atoms-one in the ring and the other in the substituent. The bridged intermediate gives rise to a second intermediate in which the nitroso group is bonded to the sulfur atom in the thioamide group. Finally, the nitroso group is transferred to GSH to form GSNO. (c) 2015 Elsevier Ltd. All rights reserved.